Analyst Holds Steady On Curis As FDA Removes Partial Clinical Hold On Leukemia Study - Curis (NASDAQ:CRIS)
Thursday, the FDA removed the partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Leukemia Phase 1/2 study of emavusertib 
Curis Inc Aim Leukemia Phase Acute Myelogenous Leukemia Myelodysplastic Syndromes Takeaim Leukemia Takeaim Lymphoma
Source: benzinga.com